In Re Regulus Therapeutics Inc. Securities Litigation

CourtDistrict Court, S.D. California
DecidedOctober 30, 2020
Docket3:17-cv-00182
StatusUnknown

This text of In Re Regulus Therapeutics Inc. Securities Litigation (In Re Regulus Therapeutics Inc. Securities Litigation) is published on Counsel Stack Legal Research, covering District Court, S.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In Re Regulus Therapeutics Inc. Securities Litigation, (S.D. Cal. 2020).

Opinion

1 2 3 4 5 6 7 8 UNITED STATES DISTRICT COURT 9 SOUTHERN DISTRICT OF CALIFORNIA 10 11 IN RE REGULUS Case No.: 3:17-cv-182-BTM-RBB THERAPEUTICS INC. Case No.: 3:17-cv-267-BTM-RBB 12 SECURITIES LITIGATION 13 ORDER GRANTING FINAL APPROVAL OF SETTLEMENT 14 . AND ATTORNEYS’ FEES 15 [ECF NOS. 46, 47] 16

17 The Court previously granted a motion for preliminary approval of the parties' 18 Class Action Settlement in this matter on May 27, 2020. (ECF No. 43.) As directed 19 by the Court's preliminary approval order, Plaintiffs filed their unopposed motion 20 for final settlement approval and motion for attorneys’ fees and costs. (ECF Nos. 21 46, 48.) The Court held a hearing on October 21, 2020. (ECF No. 52.) 22 Having considered the motion briefing, the terms of the Settlement 23 Agreement, the lack of any objections, the arguments of counsel, and the other 24 matters on file in this action, the Court GRANTS the motions for final approval and 25 attorneys’ fees and costs. 26

27 28 1 I. BACKGROUND 2 A. Procedural History 3 Plaintiffs filed the putative class action complaint on December 21, 2017 4 against Defendants Regulus Therapeutics Inc., Paul C. Grint, M.D., Joseph P. 5 Hagan, and Michael Huang, M.D., alleging Defendants made false and/or 6 misleading statements about adverse events relating to Regulus’s signature drug 7 RG-101, a hepatitis C treatment, in violation of the Securities Exchange Act of 8 1934 (“Exchange Act”). (ECF No. 1.) RG-101 was intended to cut hepatitis C 9 treatment time in half. Plaintiffs, however, allege that Defendants downplayed or 10 ignored a series of preclinical and nonclinical data and serious adverse events 11 indicating that RG-101 was prone to hepatoxicity (liver toxicity), which leads to 12 jaundice. 13 On February 20, 2017, Plaintiff Ji Lin filed a separate suit asserting the same 14 claims against Defendants. (Case No. 3:17-cv-267, ECF No. 1.) On October 26, 15 2017, the Court consolidated the two cases and appointed Levi & Korsinsky LLP 16 as Lead Counsel and Mark Appel and Michael Spitters as Co-Lead Plaintiffs. (ECF 17 No. 16.) Plaintiffs filed a consolidated complaint on December 12, 2017. (ECF 18 No. 19.) 19 On February 6, 2018, Defendants moved to dismiss the consolidated 20 complaint. (ECF No. 22.) The Court the Court granted Defendants' motion with 21 leave to amend because Plaintiffs failed to allege a specific link between RG-101, 22 liver toxicity, and the serious adverse events involving jaundice. (ECF No. 32.) 23 Without this link, the Court could not determine the preclinical or nonclinical 24 findings contradicted Defendants’ public statements or made them false or 25 misleading. (Id.) 26 On October 1, 2019, Plaintiffs filed an amended consolidated complaint. 27 (ECF No. 33.) Before Defendants could answer or respond to the amended 28 consolidated complaint, the parties reached a settlement. (ECF 38-2.) The Court 1 denied preliminary approval of the settlement because the release terms were 2 unclear and the notice procedures were deficient. (ECF No. 39.) 3 On February 7, 2020, the parties submitted an amended settlement 4 agreement (“Settlement Agreement”). (ECF No. 40.) The amended settlement 5 agreement defined the “Settlement Class” as: 6 all persons and entities that purchased or otherwise acquired shares of the publicly traded common stock of Regulus during the 7 Class Period who allege to have been damaged thereby. Excluded from the Settlement Class are (i) Defendants; (ii) members of the 8 immediate families of Defendants; (iii) any person who is or was an 9 officer or director of Regulus during or after the Class Period; (iv) any entity in which any of the Defendants had or has a controlling interest; 10 and (v) any legal representatives, agents, affiliates, heirs, beneficiaries, successors-in-interest, or assigns of any such excluded 11 party in their capacity as such. Also excluded from the Settlement Class is any Person who validly requests exclusion pursuant to the 12 requirements set forth in the Notice. 13 (ECF No. 40-2 (“Settlement Agreement”), 11:13–25 (¶ 1.34).) The Class Period 14 “means the period between February 17, 2016 and June 11, 2017, inclusive.” (Id. 15 at 5:14–15 (¶ 1.4).) 16 In its Preliminary Approval Order, the Court conditionally certified the 17 Settlement Class and provisionally appointed Levi & Korsinsky LLP as class 18 counsel and plaintiffs Mark Appel and Michael Spitters as class representative. 19 B. Terms of the Settlement Agreement 20 Under the terms of the Settlement Agreement, Defendants will pay $900,000 21 into a gross common settlement fund, without admitting liability. (Id. at 11:11–12 22 (¶ 1.33).) Of the $900,000, the Settlement Class will receive what remains after 23 subtracting the cost of any attorneys’ fees and expenses, notice and administration 24 costs, and Lead Plaintiff's service awards, and applicable taxes (the “Net 25 Settlement Fund”). (Id. at 7:17–20 (¶ 1.18).) 26 The Net Settlement Fund will be distributed among claimants on a pro rata 27 basis based on the Plan of Allocation. (Id. ¶ 1.21.) “The Plan of Allocation 28 generally measures the amount of loss that a Settlement Class member can claim 1 ||for purposes of making pro rata allocations of the Net Settlement Fund to 2 Settlement Class members who submit valid Proof of Claim and Release forms 3 “Authorized Claimants”). (ECF No. 46-5 (“Class Notice”), at 5 (§ 9).) For each 4 ||share of Regulus common stock purchased or otherwise acquired during the Class 5 ||Period, the amount of the claim will be: 6 SOLD 2/17/2016- | 6/28/2016- | 7/28/2016- | 1/30/2017 Sold on or

12 =

15 6/11/2017 16 || (/d. at 6.) 17 1. Attorneys’ Fees and Costs 18 Under the Settlement Agreement, Plaintiffs counsel agreed to seek no more 49 ||than 25 percent of the Settlement Amount, plus no more than $15,000 in litigation 20 ||costs and expenses. (Settlement Agreement, 23:25—24:10 (J 6.1); Class Notice, 21 9 (§ 18).) 22 2. Remainder 23 Any balance remaining in the Settlement Fund six months after the initial 24 || distribution shall be redistributed to Authorized Claimants who have cashed their 25 |\initial distributions, after payment of any unpaid costs or fees incurred in 26 administering the Setthement Fund for such redistribution if Lead Counsel, in 27 \\consultation with the Claims Administrator, determines that additional 28 || redistributions, after deduction of any additional fees and expenses that would be

1 incurred with respect to such redistribution, would be cost-effective. (Settlement 2 Agreement, 22:10–20 (¶ 5.5).) 3 4. Class Member Release 4 In exchange for the settlement awards, class members will release 5 defendant claims arising from the operative complaint. (Id. at 8:24–9:13 (¶ 1.25), 6 19:14–21 (¶ 4.2).) 7 C. Class Notice and Claims Administration 8 Pursuant to the Settlement Agreement, the Court appointed Analytics 9 Consulting LLC to administer the fund and to contact the class members in the 10 manner set forth in the Preliminary Approval Order. (ECF No. 43, 5 (¶ 10).) 11 II. FINAL APPROVAL OF SETTLEMENT 12 A. Legal Standard 13 A court may approve a proposed class action settlement of a class only “after 14 a hearing and on finding that it is fair, reasonable, and adequate,” and that it meets 15 the requirements for class certification. Fed. R. Civ. P. 23(e)(2). In reviewing the 16 proposed settlement, a court need not address whether the settlement is ideal or 17 the best outcome, but only whether the settlement is fair, free of collusion, and 18 consistent with plaintiff's fiduciary obligations to the class. See Hanlon v. Chrysler 19 Corp., 150 F.3d 1011, 1027 (9th Cir. 1998).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Amchem Products, Inc. v. Windsor
521 U.S. 591 (Supreme Court, 1997)
In Re Bluetooth Headset Products Liability
654 F.3d 935 (Ninth Circuit, 2011)
Valjeanne Currie v. Group Insurance Commission
290 F.3d 1 (First Circuit, 2002)
Rodriguez v. West Publishing Corp.
563 F.3d 948 (Ninth Circuit, 2009)
In Re Linerboard Antitrust Litigation
321 F. Supp. 2d 619 (E.D. Pennsylvania, 2004)
Maley v. Del Global Technologies Corp.
186 F. Supp. 2d 358 (S.D. New York, 2002)
In Re Tableware Antitrust Litigation
484 F. Supp. 2d 1078 (N.D. California, 2007)
In Re MicroStrategy, Inc. Securities Litigation
148 F. Supp. 2d 654 (E.D. Virginia, 2001)
Andre Martello Barton v. U.S. Attorney General
904 F.3d 1294 (Eleventh Circuit, 2018)
Harris v. Marhoefer
24 F.3d 16 (Ninth Circuit, 1994)
Hanlon v. Chrysler Corp.
150 F.3d 1011 (Ninth Circuit, 1998)
In re Citigroup Inc. Securities Litigation
965 F. Supp. 2d 369 (S.D. New York, 2013)
Bellinghausen v. Tractor Supply Co.
306 F.R.D. 245 (N.D. California, 2015)
United States v. Perry
559 F. Supp. 19 (E.D. Arkansas, 1982)
Class v. City of Seattle
955 F.2d 1268 (Ninth Circuit, 1992)

Cite This Page — Counsel Stack

Bluebook (online)
In Re Regulus Therapeutics Inc. Securities Litigation, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-regulus-therapeutics-inc-securities-litigation-casd-2020.